Prognostic value of elevated circulating heart-type fatty acid binding protein in patients with congestive heart failure

Arimoto, Takanori; Takeishi, Yasuchika; Shiga, Ryoko; Fukui, Akio; Tachibana, Hidetada; Nakatani, Naoki; Hirono, Osamu; Nitobe, Joji; Miyamoto, Takuya; Hoit, Brian D.

doi:10.1016/j.cardfail.2004.03.005

Cited by 70 publications

(52 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[17][18][19] H-FABP levels are increased in patients with advanced CHF because of leakage of cytosolic proteins from cardiomyocytes affected by the ongoing myocardial damage. 5 We previously reported that H-FABP was more sensitive than troponin T, a myofibrillar component, for detecting ongoing myocardial damage. 6 Recently it was reported that inflammatory markers, such as high-sensitivity C-reactive protein (hs-CRP) and tumor necrosis factor-alpha (TNF-), were related to decreasing functional status and provide important prognostic information about the morbidity and mortality of CHF patients.…”

Section: Discussionmentioning

confidence: 99%

“…Plasma BNP levels were measured using a commercially available specific radioimmunoassay for human BNP (Shiono RIA BNP assay kit, Shionogi Co Ltd, Tokyo, Japan). 5 H-FABP The venous blood samples were immediately centrifuged at 2,500 G for 15 min at 4°C to measure serum H-FABP levels. The clarified serum samples were frozen, stored at -70°C, and thawed just before assay.…”

Section: Assays Of Bnp H-fabp and Ptx3mentioning

confidence: 99%

See 1 more Smart Citation

Risk Stratification of Chronic Heart Failure Patients by Multiple Biomarkers Implications of BNP, H-FABP, and PTX3

Ishino

Takeishi

Niizeki

et al. 2008

Circ J

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Assays Of Bnp H-fabp and Ptx3mentioning

confidence: 99%

Risk Stratification of Chronic Heart Failure Patients by Multiple Biomarkers Implications of BNP, H-FABP, and PTX3

Ishino

Takeishi

Niizeki

et al. 2008

Circ J

Self Cite

View full text Add to dashboard Cite

“…In the clinical studies, serum H-FABP level is also elevated under heart failure, hypertension, aortic valve regurgitation, renal dysfunction and muscular exercise [17][18][19][20] . Our study demonstrated that H-FABP had a specificity that was slightly lower than CK-MB and cTnT, and was not superior to MYO in any time period within 12 h after onset of the symptoms.…”

Section: Discussionmentioning

confidence: 99%

Point-of-care test of heart-type fatty acid-binding protein for the diagnosis of early acute myocardial infarction

Li²,

Liang

et al. 2010

Acta Pharmacol Sin

View full text Add to dashboard Cite

“…On the other hand, it has been demonstrated that the serum level of H-FABP is increased in patients with advanced heart failure, and H-FABP is a marker for myocardial cell injury and prognosis in chronic heart failure. 35) Niizeki, et al measured serum H-FABP and troponin T levels in 126 consecutive heart failure patients at hospital admission. 36) They found that the positive rate of H-FABP was higher than that of troponin T in all heart failure patients (46% [58/126] versus 26% [33/126], P < 0.0001), and in severe heart failure (NYHA III/IV) patients (69% [34/49] versus 47% [23/49], P = 0.0121).…”

Section: )mentioning

confidence: 99%

Biomarkers in Heart Failure

Takeishi

2014

Int. Heart J.

Self Cite

View full text Add to dashboard Cite

SummaryAppropriate use of biomarkers is clinically important for identifying heart failure in its early stage, optimizing risk stratification, and managing patients. This article describes established and traditional biomarkers as well as novel biomarkers reflective of myocardial stress, myocardial damage, extracellular matrix, oxidative stress, inflammation, renal function, micro RNAs, and heart failure with preserved left ventricular ejection fraction. This review focuses on the recent advances in cardiac and non-cardiac biomarkers of heart failure and their appropriate use in clinical practice. (Int Heart J 2014; 55: 474-481) Key words: BNP, NT-proBNP, ST2, Troponin, H-FABP, Galectin-3, Cystatin C, Pentraxin 3 C ardiovascular diseases are the predominant cause of death in developed countries. Among the afflicted, patients with heart failure are increasing, and this complex syndrome is becoming a public health problem, especially with the aging of populations. To establish diagnostic, therapeutic, and prognostic strategies, the identification of reliable biomarkers for heart failure is necessary.1,2) Although a number of biomarkers have been developed, the ideal biomarkers should meet certain criteria: 1) non-invasive sample collection, 2) a high degree of sensitivity and specificity, 3) able to detect the disease at an early stage, 4) sensitivity high enough to reflect relevant changes in disease conditions, 5) a long halflife within the sample, 6) rapid measurement system responding to clinical needs, and 7) low cost. 3,4) In this article, the focus will be on the recent advances in cardiac and non-cardiac biomarkers of heart failure and their appropriate use in clinical practice. Myocardial Stress MarkersB-type natriuretic peptide: B-type natriuretic peptide (BNP) is a well-established biomarker, extensively used for the diagnosis and prognosis of patients with heart failure. BNP is a cardiac hormone, identified as the second compound of the natriuretic peptide family and secreted predominantly from the ventricle in response to mechanical overload. 5) In the failing heart, increased wall stress and neurohormonal activation facilitate BNP secretion chiefly from ventricular myocytes. BNP promotes diuresis, vasodilatation, and attenuation of renin and aldosterone secretion. Tsutamoto, et al initially measured plasma levels of BNP in 85 patients with chronic heart failure and a left ventricular ejection fraction (LVEF) of less than 0.45. 6)The plasma levels of BNP increased in proportion to the severity of heart failure. Plasma levels of BNP were 5-fold higher in non-survivors than in survivors. Among clinical and hemodynamic parameters, Cox proportional hazard analysis revealed that only plasma BNP (P < 0.0001) and pulmonary capillary wedge pressure (P = 0.003) were significant independent predictors of mortality in patients with heart failure. Plasma levels of BNP provided prognostic information independent of other variables previously associated with a poor prognosis. To date, a number of studies have r...

show abstract

Prognostic value of elevated circulating heart-type fatty acid binding protein in patients with congestive heart failure

Cited by 70 publications

References 14 publications

Risk Stratification of Chronic Heart Failure Patients by Multiple Biomarkers Implications of BNP, H-FABP, and PTX3

Risk Stratification of Chronic Heart Failure Patients by Multiple Biomarkers Implications of BNP, H-FABP, and PTX3

Point-of-care test of heart-type fatty acid-binding protein for the diagnosis of early acute myocardial infarction

Biomarkers in Heart Failure

Contact Info

Product

Resources

About